It wasn’t just media news that caused supplement companies to start searching for hoodia gordonii supplies. Press releases by Phytopharm, a British pharmaceutical company, about researching hoodia and negative effects that might be related to hoodia caused the original stir in medical supplement industry.
Phytopharm has two operating divisions; a plant extract division and a pharmaceutical division. In June of 1997, Phytopharm announced that “a naturally occurring appetite suppressant is usually to be developed into a prescription medicine by Phytopharm “.This was to be Phytopharm’s hoodia gordonii product. News of a naturally occurring appetite suppressant sent, not only supplement companies, but people who needed to lose excess weight searching with this “naturally occurring appetite suppressant “.At that time, everyone expected Phytopharm’s hoodia gordonii product to be a prescription drug although it was consistently known by the company as a “natural anti-obesity treatment “.Their collaboration with Pfizer, another pharmaceutical company, to analyze hoodia and negative effects that could be caused by hoodia use only supported the proven fact that Phytopharm’s hoodia gordonii would be a prescription drug. Now, since they’ve partnered with Unilever, not really a pharmaceutical company, it is somewhat unclear what Phytopharm’s hoodia gordonii product will be. They do seem focused on the proven fact that Phytopharm’s hoodia gordonii is likely to be better than products that are on the market.
Phytopharm’s product development strategy begins using what they call “proof of principle” clinical testing. These tests are made to determine if a product has the potential to be safe and effective. Proof of principle testing of Phytopharm’s hoodia gordonii product began in March of 2001. News about hoodia and negative effects were released following this first phase was completed in December of 2001. Uganda news papers This was a naturally occurring substance and there were no negative effects associated with its use. After completing the original clinical testing, Phytopharm’s strategy advances to the visit a partner company for “late stage development, sales and marketing “.The partner company for Phytopharm’s hoodia gordonii product is Unilever, manufacturers of food products, dietary supplements and non-prescription medications. Among their more famous products is “Slim Fast “.Phytopharm remains researching and investigating the chance or perhaps a drug to take care of metabolic disorder and hoodia gordonii is the cornerstone with this drug.
Phytopharm attempts to obtain patents for naturally occurring substances. “Phytopica” is just a Phytopharm product for the treatment of dermatitis in dogs and was just released in April of 2006. Phytopharm’s hoodia gordonii product is patented, but they’ve had greater than a little trouble keeping other manufacturers of natural products from selling their particular hoodia products. In May of 2006, they announced that these were aware that others were selling hoodia gordonii as an appetite suppressant and that they thought that this may be patent infringement. They said that they had contacted the correct authorities. The issue is that the naturally occurring product can’t be patented. If Phytopharm’s hoodia gordonii product is exclusive and therefore stronger, safer and better compared to hoodia products that are on the market, then how could there be patent infringement and why would they be concerned about companies that are selling what they imply are inferior products?
There’s no comparison involving the known side aftereffects of hoodia and negative effects related to appetite suppressants which contain stimulants. Products which contain both hoodia and stimulants could develop a problem. It is thought that problems with Ephedra arose consequently to be blended with caffeine and other stimulants. The situation was that this could not be proven without endangering human health. Hopefully, Phytopharm’s hoodia gordonii product is likely to be stimulant free as are lots of the hoodia products that are on the market.